HIV-related pulmonary arterial hypertension: Clinical presentation and management

AIDS

Volumn 22, Issue SUPPL. 3, 2008, Pages

  Sitbon, Olivier ^a,b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Service Pneumologie   (France)

Author keywords

Bosentan; HIV; Pulmonary arterial hypertension; Treatment algorithm

Indexed keywords

ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; INDINAVIR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SAQUINAVIR; SILDENAFIL;

CLINICAL FEATURE; CONSERVATIVE TREATMENT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OXYGEN SUPPLY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EPOPROSTENOL; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY ARTERY; PULMONARY CIRCULATION; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE, INTRAVENOUS; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 55249102429     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000327517.62665.ec     Document Type: Review

References (35)

1. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268-1271.
2. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108-113.
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
4. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133-1141.
5. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433-1439.
6. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89:2722-2727.
7. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J Med 2006; 73:1037-1044.
8. Opravil M, Pechère M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155:990-995.
9. Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 2004; 4:117-131.
10. Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006; 42:391-395.
11. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44:493-499.
12. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection: improved haemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178-1185.
13. Barbara G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92:1164-1166.
14. Torre D, Pugliese A. Impact of antiretroviral therapy among HIV-1-infected patients with pulmonary hypertension. Clin Infect Dis 2004; 39:1549-1550.
15. Pellicelli AM, Palmieri F, D'Ambrosio C, Rianda A, Boumis E, Girardi E, et al. Role of human immunodeficiency virus in primary pulmonary hypertension - case reports. Angiology 1998; 49:1005-1011.
16. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278.
17. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1 Suppl.):35S-62S.
18. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928.
19. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AH, Parent F, et al. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:A210.
20. Rossi DR, Rathbun RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy 2002; 22:1312-1316.
21. Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78:143-153.
22. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846-1850.
23. Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med 1997; 127:1043.
24. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, Lazaro Salvador M, Gomez Sanchez MA, Delgado Jimenez JF, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003; 56:421-425.
25. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23:321-326.
26. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15:1747-1748.
27. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003; 17:1714-1715.
28. Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999; 13:F101-F107.
29. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50:99-107.
30. Pfizer Ltd. Sildenafil summary of product characteristics. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID= 17443#CONTRAINDICATIONS. Accessed: 21 September 2007.
31. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212-1217.
32. Humbert M, Hoeper MM, Keily DG, Sepal E, Carlsen J. Long-term safety profile of bosentan in patients with pulmonary arterial hypertension associated with HIV: results from the Tracleer PMS database. 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, Colorado, poster 745.
33. Aschmann YZ, Kummer O, Linka A, Wenk A, Azzola A, Bodmer M, et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. Ther Drug Monit 2008; 30:130-134.
34. Revatio product insert. Available at: http://xpil.medicines.org.uk/ ViewPil.aspx?docid=18411. Accessed: 9 June 2008.
35. Tracleer summary of product characteristics. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=10231. Accessed: 9 June 2008.